BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18596742)

  • 1. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
    Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
    J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
    Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
    Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].
    Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
    Avivi I; Cohen YC; Joffe E; Benyamini N; Held-Kuznetsov V; Trestman S; Terpos E; Dimopoulos MA; Kastritis E
    Hematol Oncol; 2017 Dec; 35(4):734-740. PubMed ID: 27641057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chains: diagnostic and prognostic value in multiple myeloma.
    Sthaneshwar P; Nadarajan V; Maniam JA; Nordin N; Gin Gin G
    Clin Chem Lab Med; 2009; 47(9):1101-7. PubMed ID: 19728852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
    Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
    Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and validation of serum free light chain reference intervals in an ethnic Chinese population.
    Liang YF; Chen WM; Wang QT; Zhai YH; Yang YJ; Liu JY; Levoguer A; Sun WH
    Clin Lab; 2014; 60(2):193-8. PubMed ID: 24660530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin free light chains and solitary plasmacytoma of bone.
    Dingli D; Kyle RA; Rajkumar SV; Nowakowski GS; Larson DR; Bida JP; Gertz MA; Therneau TM; Melton LJ; Dispenzieri A; Katzmann JA
    Blood; 2006 Sep; 108(6):1979-83. PubMed ID: 16741249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
    El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
    Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
    Kasamatsu T; Ozaki S; Saitoh T; Konishi J; Sunami K; Itagaki M; Asaoku H; Cho T; Handa H; Hagiwara S; Wakayama T; Negoro A; Takezako N; Harada N; Kuroda Y; Nakaseko C; Miyake T; Inoue N; Hata H; Shimazaki C; Ohno T; Kuroda J; Murayama T; Kobayashi T; Abe M; Ishida T; Nagura E; Shimizu K
    Hematol Oncol; 2018 Dec; 36(5):792-800. PubMed ID: 30176173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.
    Kumar S; Zhang L; Dispenzieri A; Van Wier S; Katzmann JA; Snyder M; Blood E; DeGoey R; Henderson K; Kyle RA; Bradwell AR; Greipp PR; Rajkumar SV; Fonseca R
    Leukemia; 2010 Aug; 24(8):1498-505. PubMed ID: 20520636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.